Positive high-level results in trials of its baxdrostat drug to treat hypertension provided AstraZeneca shares with a ...

Delayed diagnosis of hypertension after initial elevated BP measurement was tied to lower rates of antihypertensive drug ...

In a new clinical practice guideline, the Endocrine Society advises universal screening of those with hypertension by ...

Baxdrostat, which AstraZeneca acquired in a 2023 buyout of CinCor Pharma, could become a new treatment for people whose ...

Dr. Chen echoes the American Heart Association's recommendation for daily salt intake, which is 2,300 mg per day. However, Dr ...

Researchers found a 30% increased risk of cardiovascular events in patients whose diagnosis was delayed by more than a year ...

AstraZeneca’s $1.3 billion bet on CinCor Pharma and its mid-phase hypertension drug baxdrostat seems to have paid off based ...

Fewer than 10 percent of people with hypertension had their blood sugar under control & fewer than 66 percent of diabetics ...

At two doses, baxdrostat demonstrated significant reduction in mean seated systolic BP vs. placebo at 12 weeks among patients with uncontrolled or treatment-resistant hypertension, AstraZeneca ...